Q BioMed (Q BioMed) Gross-Profit-to-Asset % : -0.34% (As of Feb. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Q BioMed Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Q BioMed's annualized Gross Profit for the quarter that ended in Feb. 2023 was $-0.01 Mil. Q BioMed's average Total Assets over the quarter that ended in Feb. 2023 was $3.49 Mil. Therefore, Q BioMed's annualized Gross-Profit-to-Asset % for the quarter that ended in Feb. 2023 was -0.34%.

Q BioMed Gross-Profit-to-Asset % Historical Data

The historical data trend for Q BioMed's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q BioMed Gross-Profit-to-Asset % Chart

Q BioMed Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

-46.87

-7.12

-0.42

Q BioMed Quarterly Data
	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															0.59	77.78	-33.06	-13.55	-0.34

Competitive Comparison of Q BioMed's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Q BioMed's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q BioMed's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q BioMed's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Q BioMed's Gross-Profit-to-Asset % falls into.

Q BioMed Gross-Profit-to-Asset % Calculation

Q BioMed's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Nov. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Nov. 2022 )	/	( (Total Assets (A: Nov. 2021 )	+	Total Assets (A: Nov. 2022 ))	/ count )
	=	-0.009	/	( (0.809	+	3.516)	/ 2 )
	=	-0.009	/	2.1625
	=	-0.42 %

Q BioMed's annualized Gross-Profit-to-Asset % for the quarter that ended in Feb. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Feb. 2023 )	/	( (Total Assets (Q: Nov. 2022 )	+	Total Assets (Q: Feb. 2023 ))	/ count )
	=	-0.012	/	( (3.516	+	3.465)	/ 2 )
	=	-0.012	/	3.4905
	=	-0.34 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Feb. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Q BioMed Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Q BioMed's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Q BioMed (Q BioMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017

Website

https://www.qbiomed.com

Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.

Executives

William S Rosenstadt	director, 10 percent owner, officer: Chief Legal Officer	ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin	director, 10 percent owner, officer: Chief Executive Officer	10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci	director	501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay	10 percent owner	580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1